



## ASX ANNOUNCEMENT

1 July 2024

### \$1.65m Received for Sale of Equipment

---

**1 July 2024** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce that late Friday, 28 June, the Company received \$1.65 million, being the final instalment of the executed plant and equipment sale agreement with Biortica Agrimed Ltd, announced on 18 March 2024.

The sale was for a range of plant and equipment, surplus to Cann's needs. The sale price for the equipment was \$1.5 million (plus GST). Two smaller instalment payments were received during the period between the sale date and Friday's receipt.

**Authorised for release by Tony Di Pietro, Company Secretary, Cann Group Limited.**

#### For all other information please contact:

Jenni Pilcher  
Executive Director  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Tony Di Pietro  
CFO & Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

#### About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)